Yuzhuo Wang, PhDDirector, Living Tumor LaboratoryDistinguished Scientist, BC Cancer AgencySenior Scientist, Vancouver Prostate CentreProfessor, University of British Columbia675 West 10th Avenue, Room 3.122Vancouver, BC, Canada V5Z 1L3Dong Lin, PhD, MDResearch Pathologist, Living Tumor LaboratoryPeter W. Gout, PhDScientific Consultant, Living Tumor LaboratoryHonorary Associate Professor, Department of Urologic Sciences, University of British ColumbiaEmeritus Senior Scientist, Department of Experimental Therapeutics, BC Cancer Agency<675 West 10th Avenue, Room 5.108Vancouver, BC, Canada V5Z 1L3

• Introduction.- History and Evolution of PDX Cancer Models.- Establishment and Characterization of PDX Models.- Methods of Generating PDX Models.- Fidelity and Stability of PDX Models.- Applications of PDX Models.- Studies of Cancer Heterogeneity.- PDX and Cancer Stem Cells.- Modeling Cancer Metastasis.- Modeling Drug Resistance.- PDX and Biomarker Development.- PDX and Preclinical Drug Screening.- Co-clinical Trials and Personalized Cancer Therapy/Precision Medicine.- Epilogue.- Future Perspective.

Yuzhuo Wang, PhDDirector, Living Tumor LaboratoryDistinguished Scientist, BC Cancer AgencySenior Scientist, Vancouver Prostate CentreProfessor, University of British Columbia675 West 10th Avenue, Room 3.122Vancouver, BC, Canada V5Z 1L3Dong Lin, PhD, MDResearch Pathologist, Living Tumor LaboratoryPeter W. Gout, PhDScientific Consultant, Living Tumor LaboratoryHonorary Associate Professor, Department of Urologic Sciences, University of British ColumbiaEmeritus Senior Scientist, Department of Experimental Therapeutics, BC Cancer Agency<675 West 10th Avenue, Room 5.108Vancouver, BC, Canada V5Z 1L3

• Introduction.- History and Evolution of PDX Cancer Models.- Establishment and Characterization of PDX Models.- Methods of Generating PDX Models.- Fidelity and Stability of PDX Models.- Applications of PDX Models.- Studies of Cancer Heterogeneity.- PDX and Cancer Stem Cells.- Modeling Cancer Metastasis.- Modeling Drug Resistance.- PDX and Biomarker Development.- PDX and Preclinical Drug Screening.- Co-clinical Trials and Personalized Cancer Therapy/Precision Medicine.- Epilogue.- Future Perspective.

Yuzhuo Wang, PhDDirector, Living Tumor LaboratoryDistinguished Scientist, BC Cancer AgencySenior Scientist, Vancouver Prostate CentreProfessor, University of British Columbia675 West 10th Avenue, Room 3.122Vancouver, BC, Canada V5Z 1L3Dong Lin, PhD, MDResearch Pathologist, Living Tumor LaboratoryPeter W. Gout, PhDScientific Consultant, Living Tumor LaboratoryHonorary Associate Professor, Department of Urologic Sciences, University of British ColumbiaEmeritus Senior Scientist, Department of Experimental Therapeutics, BC Cancer Agency<675 West 10th Avenue, Room 5.108Vancouver, BC, Canada V5Z 1L3

• Introduction.- History and Evolution of PDX Cancer Models.- Establishment and Characterization of PDX Models.- Methods of Generating PDX Models.- Fidelity and Stability of PDX Models.- Applications of PDX Models.- Studies of Cancer Heterogeneity.- PDX and Cancer Stem Cells.- Modeling Cancer Metastasis.- Modeling Drug Resistance.- PDX and Biomarker Development.- PDX and Preclinical Drug Screening.- Co-clinical Trials and Personalized Cancer Therapy/Precision Medicine.- Epilogue.- Future Perspective.